Century Therapeutics develops allogeneic cell therapies derived from induced pluripotent stem cells (iPSCs) for cancer and immune-mediated disease. The platform aims to create off-the-shelf immune cells that can be manufactured at scale rather than patient-specific autologous products. Its programs target oncology and related indications where standardized cell therapies could broaden access beyond current CAR-T models.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -32.5 | — |
| Q3 2025 | 0 | — | -34.4 | — |
| Q4 2025 | 0 | — | -19.2 | — |
| Q1 2026 | 0 | — | -21.6 | — |
| Q2 2026 | 0 | — | -34.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Standard BioTools Inc. (LAB), Super League Enterprise, Inc. (SLE), Inflection Point Acquisition Corp. VIII (IPHX), Richmond Mutual Bancorporation, Inc. (RMBI), Palisade Bio, Inc. (PALI), Quantum-Si incorporated (QSI)